Company: NIVFW
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001213900-25-033966
Chunk: 45

Company: NewGenIvf Group Ltd
Filing Date: 2025-04-22
Form: 20-F
Item: Item 3
Chunk 45
---
 In addition, NewGenIvf may not be able to find and identify desirable acquisition targets or business opportunities
or be successful in entering into an agreement with any particular strategic partner. These transactions could also result in dilutive
issuances of equity securities or the incurrence of debt, which could adversely affect its results of operations. In addition, if the
resulting business from such a transaction fails to meet NewGenIvf’s expectations, or it fails to successfully integrate such businesses
into its own, its business, financial condition and results of operations may be adversely affected or it may be exposed to unknown risks
or liabilities. Even when NewGenIvf identifies an appropriate acquisition or investment target, it may not be able to negotiate the terms
of the acquisition or investment successfully, obtain financing for the proposed transaction, or integrate the relevant businesses into
its existing business and operations. Strategic investments or acquisitions will involve risks commonly encountered in business relationships,
including:

  difficulties in assimilating and integrating the operations, personnel, systems, data, technologies, products and services of the acquired business;  

  inability of the acquired technologies, products or businesses to achieve expected levels of revenue, profitability, productivity or other benefits;  

  difficulties in retaining, training, motivating and integrating key personnel;  

  diversion of management’s time and resources from NewGenIvf’s normal daily operations;  

  difficulties in maintaining uniform standards, controls, procedures and policies within the combined organizations;  

  difficulties in retaining relationships with customers, employees and suppliers of the acquired business;  

  risks of entering markets in which NewGenIvf have limited or no prior experience;  

  regulatory risks, including remaining in good standing with existing regulatory bodies or receiving any necessary pre-closing or post-closing approvals, as well as being subject to new regulato...  

  assumption of contractual obligations that contain terms that are not beneficial to NewGenIvf, require it to license or waive intellectual property rights or increase its risk for liability;  

  failure to further successfully develop the acquired technology;  

  liability for activities of the acquired business before the acquisition, including intellectual property infringement claims, violations of laws, commercial disputes, tax liabilities and other...  

  potential disruptions to NewGenIvf’s ongoing businesses; and  

  unexpected costs and unknown risks and liabilities associated with strategic investments or acquisitions.  

Even if the transaction is
consummated, NewGenIvf may only have limited control over the companies in which it only has minority stake, it cannot ensure that